Brains Bioceutical Set to Achieve One of the World’s First CEP for Cannabidiol Certification with th
Advancing Pharmaceutical Innovation: Brains Bioceutical's CEP Certification will Streamline Cannabinoid Drug Development, Inspired by Jazz Pharmaceuticals' CBD-Based Epilepsy Drug and 2024 $1.4 Billion Revenue Projection
SANDWICH, United Kingdom, Aug. 22, 2024 (GLOBE NEWSWIRE) - Brains Bioceutical Corp. (BBC) has achieved a groundbreaking milestone by submitting one of the world's first CEP (Certification of Suitability) application for its Cannabidiol (CBD) Active Pharmaceutical Ingredient (API) to the European Directorate for the Quality of Medicines & Healthcare (EDQM). This landmark achievement demonstrates BBC's CBD as meeting the highest industry standard for pharmaceutical-grade cannabinoid products.
The CEP confirms that BBC's CBD meets European Pharmacopoeia (Ph. Eur.) standards, a crucial endorsement for pharmaceutical manufacturers in Europe, Canada, Australia, Japan, and the US. This certification streamlines regulatory processes, ensuring high quality, consistency, and safety for global markets.
Additional advantages of the CEP include:
- Facilitating and simplifying interactions between regulators and industry, ensuring that substances used in pharmaceutical production meet European Pharmacopoeia standards and comply with relevant EU legislation.
- Easing the management of investigational medicinal product for medicinal products.
- Serving as a complement and bridge between European Pharmacopoeia monographs and the regulatory dossier requirements for medicinal products.
- Acting as a link between health authorities and industry, enhancing communication and cooperation.
Ricky Brar, CEO and Chairman of Brains Bioceutical Corp., emphasized the importance of this certification in the company's long-term strategy. "Achieving a CEP for our Cannabidiol Active Pharmaceutical Ingredient is a pivotal step in our journey to lead the global cannabinoid market. It reinforces our commitment to quality and innovation, and it positions Brains Bio to set the standard for the industry. This is not just about meeting regulatory requirements—it's about exceeding them and setting a new benchmark for what pharmaceutical-grade cannabinoid products should be."
Dean Billington, Chief Operating Officer of Brains Bioceutical Corp., added, "Our submission to the EDQM is a testament to the hard work and dedication of our team. The CEP will provide a significant competitive advantage, ensuring that our Cannabidiol API is recognized as a top-tier ingredient for pharmaceutical use. We are proud to be at the forefront of this rapidly evolving industry, driving excellence in every aspect of our operations."
The global demand for cannabinoid-based pharmaceuticals remains robust, evidenced by Epidiolex, which Jazz Pharmaceuticals projects will generate approximately $1.4 billion in revenue in 2024 [1]. This reflects ongoing growth and demand for high-quality pharmaceutical cannabinoid products.
The EDQM's review process, initiated on August 8, 2024, will take approximately 115 working days. Successful granting of a CEP will confirm that Brains Bio's CBD meets, the stringent Ph. Eur. requirements.
This CEP application effort underscores Brains Bio's unwavering commitment to setting new standards for the cannabinoid industry. This builds on Brains Bio's EU GMP and controlled substances licenses. By aligning its CBD API with the rigorous criteria of the European Pharmacopoeia, Brains Bio is not only participating in the market but actively shaping its future.
As part of our strategic partnership, Brains Bioceutical and DSM-Firmenich have joined forces to leverage their combined expertise in cannabinoid research and development. Together with Brains Bioceutical – manufacturer of high-quality pharma-grade cannabinoids – DSM-Firmenich offers an end-to-end innovation platform designed to support early-stage cannabinoid drug development and realize the potential of CBD- based formulations. Its capabilities include leading-edge formulation expertise, a global network of regulatory specialists, and preclinical and clinical study proficiency. The company also has the capacity to provide customized solutions depending on the therapeutic area and drug delivery objective. To learn more about how DSM-Firmenich's cannabinoid innovation platform is helping to elevate patient health, visit: www.dsm.com/cannabinoid-actives.
About Brains Bioceutical Corp.
Brains Bioceutical is the leader in evidence-based and science-led pioneer of natural plant-based health and wellness solutions.
Brains Bio is a leading manufacturer of the highest quality natural and pure active pharmaceutical ingredients (APIs), with a unique suite of licenses and registrations, Brains Bio is strategically positioned to take advantage of the complex regulatory environment, securing its first mover and product quality advantage. Brains Bio is diversified across the pharmaceutical, medical, and nutraceutical sectors within the rapidly growing cannabinoid market, resulting in a strong and unique value proposition.
[1] https://investor.jazzpharma.com/investors
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/b460b7ca-9a31-4a41-a012-23d26e61ef5d
Contact:
INFO@BRAINSBIO.COM
BRAINSBIO.COM
1-855-927-2476
- 万纬物流与中物联人资委共办“数智转型、赋能发展”沙龙
- AI技术发展趋势及心理行业消费应用产品商业深度洞察
- 以旧换新换什么最合适?长虹美菱来支招!
- 谷器数据入选2024新型工业化优秀实践案例
- VLP微型隔膜液泵在IVD医疗设备上的应用分析报告
- 《中国智库专家典范》暨胸怀鸿鹄之志尽显大师之风·赵连甲
- Irdeto Wins for Anti-Piracy at the 2024 Cybersecurity Excellence Awards
- 香港成功争取主办2026年狮子会国际年会
- 苏一堂紫砂电饭煲,品味健康生活好味道
- 临商银行北京路支行走进曲沂社区开展“安全宣传咨询日”活动
- 浪漫七夕 红色郧西 牛郎织女虚拟数字人“点亮”红色文旅
- Novotech Publishes Duchenne Muscular Dystrophy Landscape Report to Support Biotech Research Planning
- 商安信ESG PRO | 央视钦点“中国ESG榜样”!宁德时代究竟做对了什么
- IVECO and Foton announce joint exploration into future synergies
- 《FabriX》型格登陆全球潮流盛事「ComplexCon香港」 体验全新流线型设计扩增实境试衣间 沉浸于革新时装购物体验
- Fluence Surpasses 20 GWh of Deployed and Contracted Battery-based Energy Storage Systems Globally
- 快手主播李香周助力推动 K-beauty风潮谈背后成功秘诀
- 探索家装卫浴美学的魅力,这款热水器可以让你的卫浴间改天换地
- 驻村帮扶,节前慰问暖人心——平安养老险陕西分公司积极开展春节前慰问及调研工作
- 【新书推介】《登门槛效应》教您轻松驾驭人际关系
推荐
- 大家一起关注新疆乌什7.1级地震救援见闻 看到热气腾腾的抓饭马上就要出锅、村里大家 资讯
- 新增供热能力3200万平方米 新疆最大热电联产项目开工 昨天(26日),新疆最大的热电联产项目—&md 资讯
- 中国减排方案比西方更有优势 如今,人为造成的全球变暖是每个人都关注的问 资讯
- 透过数据看城乡居民医保“含金量” 缴费标准是否合理? 记者从国家医保局了解到,近期,全国大部分地区 资讯
- 私域反哺公域一周带火一家店! 三四线城市奶茶品牌茶尖尖两年时间做到GMV 资讯
- 看新东方创始人俞敏洪如何回应董宇辉新号分流的? (来源:中国证券报) 东方甄选净利润大幅下滑 资讯
- 一个“江浙沪人家的孩子已经不卷学习了”的新闻引发议论纷纷 星标★ 来源:桌子的生活观(ID:zzdshg) 没 资讯
- 国足13次出战亚洲杯首次小组赛0进球 北京时间1月23日消息,2023亚洲杯小组 资讯
- 产业数字化 为何需要一朵实体云? 改革开放前,国内供应链主要依靠指标拉动,其逻 资讯
- 男子“机闹”后航班取消,同机旅客准备集体起诉 1月4日,一男子大闹飞机致航班取消的新闻登上 资讯